Edition:
United States

Nektar Therapeutics (NKTR.OQ)

NKTR.OQ on NASDAQ Stock Exchange Global Select Market

89.60USD
23 Feb 2018
Change (% chg)

$1.39 (+1.58%)
Prev Close
$88.21
Open
$88.70
Day's High
$89.90
Day's Low
$87.13
Volume
426,452
Avg. Vol
811,132
52-wk High
$99.02
52-wk Low
$12.51

Chart for

About

Nektar Therapeutics is a biopharmaceutical company that discovers and develops medicines in areas of high unmet medical need. The Company's research and development pipeline of new investigational drugs includes treatments for cancer, auto-immune disease and chronic pain. It leverages its chemistry platform to discover and... (more)

Overall

Beta: 1.95
Market Cap(Mil.): $14,109.11
Shares Outstanding(Mil.): 157.47
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 195.87 16.59
EPS (TTM): -- -- --
ROI: -- -0.71 35.07
ROE: -- -3.37 17.79

Bristol-Myers to pay $1.85 billion in cancer deal with Nektar

Bristol-Myers Squibb Co will pay Nektar Therapeutics $1.85 billion for a global development and profit-sharing deal on a promising Nektar cancer drug, the companies announced on Wednesday.

Feb 14 2018

UPDATE 1-Bristol-Myers to pay $1.85 bln in cancer deal with Nektar

Feb 14 Bristol-Myers Squibb Co will pay Nektar Therapeutics $1.85 billion for a global development and profit-sharing deal on a promising Nektar cancer drug, the companies announced on Wednesday.

Feb 14 2018

Bristol-Myers to pay $1.85 bln in cancer deal with Nektar

Feb 14 Bristol-Myers Squibb Co will pay Nektar Therapeutics $1.85 billion in cash and share purchase for a global development and commercialization deal on a promising Nektar cancer drug, the companies announced on Wednesday.

Feb 14 2018

BRIEF-Nektar Therapeutics Says Received Notice Of Termination From Bayer Of Co-Development, License, Co-Promotion Agreement

* NEKTAR THERAPEUTICS - ‍ON DEC 14, CO RECEIVED NOTICE OF TERMINATION FROM BAYER OF CO-DEVELOPMENT, LICENSE,CO-PROMOTION AGREEMENT, DATED AUG 1, 2007​ Source text: (http://bit.ly/2BsgSdG) Further company coverage:

Dec 15 2017

BRIEF-Nektar Therapeutics Says Received Notice Of Termination From Daiichi Of Collaboration Agreement

* NEKTAR THERAPEUTICS - ON DEC 6, CO RECEIVED NOTICE OF TERMINATION FROM DAIICHI OF COLLABORATION AGREEMENT WHICH WILL BECOME EFFECTIVE AS OF FEB 4, 2018

Dec 12 2017

BRIEF-Nektar Therapeutics estimates wind down costs of $3 mln to $4 mln related to ceasing clinical program

* Nektar Therapeutics says estimates that it will incur about $3 million to $4 million of wind-down costs

Nov 24 2017

BRIEF-EMA recommends against approval after re-examination of Nektar's drug onzeald

* EU MEDICINES AGENCY RECOMMENDS AGAINST APPROVAL AFTER RE-EXAMINATION OF NEKTAR'S DRUG ONZEALD FOR TREATMENT OF BREAST CANCER WHICH HAS SPREAD TO BRAIN‍​ Source text (http://bit.ly/2zxBcXv) Further company coverage:

Nov 10 2017

BRIEF-Nektar Therapeutics reports Q3 earnings per share $0.39

* Nektar Therapeutics reports financial results for the third quarter of 2017

Nov 07 2017

BRIEF-Nektar Therapeutics presents preclinical data on NKTR-358

* Presents preclinical data on NKTR-358, a first-in-class regulatory T Cell stimulator, at 2017 American College of Rheumatology Annual Meeting Source text for Eikon: Further company coverage:

Nov 07 2017

BRIEF-Nektar Therapeutics initiates propel clinical study

* Nektar Therapeutics initiates propel clinical study to evaluate combination of NKTR-214, a CD122-biased agonist, with tecentriq (atezolizumab) or keytruda (pembrolizumab) Source text for Eikon: Further company coverage:

Sep 12 2017

Competitors

  Price Chg
Takeda Pharmaceutical Co Ltd (4502.T) ¥5,956 +70.00
Eisai Co., Ltd (4523.T) ¥5,631 +61.00
NOF CORPORATION (4403.T) ¥2,979 +18.00
Dr.Reddy's Laboratories Ltd (REDY.NS) Rs2,167.05 +43.60
Novo Nordisk A/S (NOVOb.CO) kr.323.70 +3.15
Pfizer Inc. (PFE.N) $36.26 +0.52
Novartis AG (NOVN.S) CHF79.38 -0.60
Roche Holding Ltd. (ROG.S) CHF222.05 -1.25
Roche Holding Ltd. (RO.S) CHF225.80 -0.60
GlaxoSmithKline plc (GSK.L) 1,296.00 -7.00

Earnings vs. Estimates